Last updated on May 2020

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression


Brief description of study

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FR. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha (FR) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.

Detailed Study Description

Patients will be randomized to either mirvetuximab soravtansine (MIRV) or Investigator's Choice chemotherapy (paclitaxel, PEGylated liposomal doxorubicin, or topotecan).

Clinical Study Identifier: NCT04209855

Find a site near you

Start Over

Holy Name Medical Center

Teaneck, NJ United States
  Connect »

Sarasota Memorial Hospital

Sarasota, FL United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

Holy Cross Hospital

Silver Spring, MD United States
  Connect »

USOR: Texas Oncology, P.A.

Sugar Land, TX United States
  Connect »

Illinois Cancer Specialists

Arlington Heights, IL United States
  Connect »

University of Virginia Health System

Charlottesville, VA United States
  Connect »

West Virginia University- MBRCC

Morgantown, WV United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »